Clonal chromosomal aberrations in patients with aplastic anemia at the disease onset and transformation

Terapevticheskii Arkhiv

Volumn 78, Issue 7, 2006, Pages 31-37

  Olshanskaya, Yu V ^a   Mikhailova, E A ^a   Domracheva, E V ^a   Udovichenko, A I ^a   Davidyan, Yu R ^a   Vodinskaya, L A ^a   Zakharova, A V ^a   Kokhno, A V ^a   Kaplanskaya, I B ^a   Tikhonova, L Yu ^a   Tsvetaeva, N V ^a   Parovichnikova, E N ^a   Savchenko, V G ^a  

^a NONE

Author keywords

Acute leukemia; Aplastic anemia; Chromosomal aberrations; Myelodysplastic syndrome; Transformation

Indexed keywords

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW CELL; CASE REPORT; CELL CLONE; CELL TRANSFORMATION; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME DELETION; FEMALE; GENETICS; HUMAN; KARYOTYPING; MALE; MIDDLE AGED; MONOSOMY; MYELODYSPLASTIC SYNDROME; PATHOLOGY;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE MARROW CELLS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 7; CLONE CELLS; FEMALE; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MONOSOMY; MYELODYSPLASTIC SYNDROMES;

EID: 33747751895     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Young N. S., Maciejewski J. P. The pathophysiology of acquired aplastic anemia. N. Engl. J. Med. 1997; 336: 1365-1372.
2. Young N., Speck B. Antithymocyte and antilymphocyte globulins: clinical trials and mechanism of action. Progr. Clin. Biol. Res. 1984; 148: 221-226.
3. Tichelli A., Gratwohl A., Wursch A. et al. Late haematological complications in severe aplastic anaemia. Br. J. Haematol. 1988; 69: 413-418.
4. De Planque M. M., Kluin-Nelemans H. C., van Krieken H. J. et al. Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. Br. J. Haematol. 1988; 70: 55-62.
5. De Planque M. M., Bacigalupo A., Wursch A. et al. Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT). Br. J. Haematol. 1989; 73: 121-126.
6. Maciejewski J. P., Risitano A., Sloand E. M. et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99: 3129-3135.
7. Mikhailova N., Sessarego M., Fugazza G. et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica 1996; 81: 418-422.
8. La Starza R., Matteucci C., Crescenzi B. et al. Trisomy 6 is the hallmark of a dysplastic clone in bone marrow aplasia. Cancer Genet. Cytogenet. 1998; 105: 55-59.
9. Geary C. G., Harrison C. J., Philpott N. J. et al. Abnormal cytogenetic clones in patients with aplastic anemia: response to immunosuppressive therapy. Br. J. Haematol. 1999; 104: 271-274.
10. Ishiyama K., Karasawa M., Miyawaki S. Aplastic anaemia with 13q-: a benign subset of bone marrow failure responsive to immunosuppressive therapy. Br. J. Haematol. 2002; 117: 747-750.
11. Seabright M. A rapid banding technique for human chromosomes. Lancet 1971; 2: 71-72.
12. Mitelman F. S., ed. An International system for human cytogenetic nomenclature (1995). Basel: Karger AG; 1995.
13. Appelbaum F., Barral J., Storb R. et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp. Hematol. 1987; 15: 1134-1139.
14. Keung Y.-K., Pettenati M. J., Julia M. C. et al. Bone marrow cytogenetic abnormalities of aplastic anemia. Am. J. Hematol. 2001; 66: 167-171.
15. Ohga S., Ohara A., Hibi S. et al. Treatment responses of childhood aplastic anaemia with chromosomal aberrations at diagnosis. Br. J. Haematol. 2002; 118: 313-319.
16. Moormeir J. A., Rubin C. M., LeBeau M. M. et al. Trisomy 6 a recurring cytogenetic abnormality associated with marrow hypoplasia. Blood 1991; 77: 1397-1398.
17. Tichelli A., Socie G., Marsh J. et al. For the EBMT-SAA Working Party. Cytogenetic abnormalities in aplastic anemia. Bone Marrow Transplant. 1996; 7 (suppl. 1): 268a.
18. Tuzuner N., Cox C., Rowe J. et al. Hypoplastic myelodysplasia (MDS): new proposals. Br. J. Haematol. 1995; 91: 612-617.
19. Wun T., Lewis J. P. Clonal remission in aplastic anemia after treatment with anthimocytic globulin. Am. J. Hematol. 1992; 40: 229-231.
20. Young N. S., Maciejewski J. The pathophysiology of acquired aplastic anemia. N. Engl. J. Med. 1997; 336: 1365-1372.
21. Wolk A., Simon-Stoos K., Nami I. et al. A mouse model of immuno-mediated aplastic anemia. Blood 1998; 91 (suppl. 1): 158a-159a.
22. Zeng W., Maciejewski J. P., Chen G. et al. Limited heterogenety of T-cell receptor BV usage in aplastic anemia. J. Clin. Invest. 2001; 108: 765-773.
23. Bacigalupo A., Chaple M., Hows J. et al. Treatment of aplastic anemia (AA) with antilymphocytic globulin (ALG) and methylprednisolone (Mpred) with or without androgenes: a randomized trial from the EBMT SAA working party. Br. J. Haematol. 1993; 83: 145-151.
24. Socie G., Henry-Amar M., Bacigalupo A. et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation - Severe Aplastic Anaemia Working Party. N. Engl. J. Med. 1993; 329: 1152-1157.
25. Ohara A., Kojima S., Hamajima H. et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009-1013.
26. Kaito K., Kobayashi M., Katayama T. et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br. J. Haematol. 1998; 103: 297-303.